Integration and Adoption Analysis of Digital Health Monitoring Devices: Reflections of a Pilot Project (Preprint)

• DOI: 10.2196/preprints.11810
• Publication Date: 2018-09-17T12:15:13Z
• Authors: Christopher Park; Emmamuzo Otobo; Jason Rogers; Farah Fasihuddin; Shashank Garg; Sarthak Kakkar; Sean Pinney; Jennifer Ullman; Chloe Yang; Zahin Roja; Kritika Singh; Vinod Kumar; Divya Madisetty; Ashish Atreja
• Keywords: Digital Health; Vital signs

<sec> <title>BACKGROUND</title> Congestive heart failure (CHF) is a disease that affects about 6.5 million people in the United States with mortality rate of around 30%. With incidence projected to rise by 46% exceed 8 cases 2030, projections estimate total CHF costs will increase nearly $70 billion. Recently, advent remote monitoring technology has significantly broadened scope physician’s reach chronic management. Using remotely monitored health data, providers may be able better manage and predict their patients’ outcomes, leading reduced hospital admission costs. </sec> <title>OBJECTIVE</title> This project aimed demonstrate feasibility digital medicine engagement platform for patients, including identifying factors associated increased risk readmission assessing usage patterns devices. <title>METHODS</title> The included 60 patients admitted Mount Sinai Hospital CHF. A Rx.Health, called RxUniverse, was used prescribe HealthPROMISE iHealth mobile apps. Patients updated recorded CHF-related symptoms quality life measures daily on HealthPROMISE. Vital sign blood pressure weight, were collected through an ambulatory system integrated app complementary consumer grade Bluetooth-connected smart devices (blood cuff scale). Physicians notified abnormal patient weight change readings further action left discretion. We statistical analyses determine 30-day all-cause readmission. <title>RESULTS</title> Overall, there six readmissions (10%), compared national rates 25%. Single marital status (P&lt;.1) history percutaneous coronary intervention Readmitted also less likely have been previously prescribed angiotensin converting enzyme inhibitors or II receptor blockers (P&lt;.05). Notably, readmitted utilized monitors than non-readmitted aged 70 more frequently average those over 70, though these trends did not significance. percentage using at least once dropped steadily from 83% first week after discharge fourth week. Additionally, 88% monitor 4 times 62% 10 times, some multiple per day. <title>CONCLUSIONS</title> Given increasing burden CHF, need effective sustainable following discharge. identified clinical social as well identify targetable populations could benefit most integration monitoring. In addition, we demonstrated interventions driven real-time vitals data greatly aid reducing while improving outcomes. Future studies should seek implement confirm large-scale population.